Title: The Role of Seladelpar in Primary Biliary Cholangitis: A Systematic Review and Meta-
Analysis
Version: 0 Date: 06 Feb 2025
Reviewer's report:
This article systematically evaluated the efficacy and safety of Seladelpar, a selective PPAR-
# agonist, for the treatment of primary biliary cholangitis (PBC). To address the conflicting
efficacy conclusions and insufficient long-term safety evidence in existing studies, the authors
integrated clinical trial data to clarify the clinical value of Seladelpar through a systematic review
and meta-analysis, and explored future research directions, aiming to provide an evidence-based
rationale for optimising therapeutic strategies for PBC.However, some drawbacks in the paper
necessitate revisions prior to publication.
1.There are some typos errors and grammatical issues through the manuscrip.
2.The authors retrieved studies up to March 2024, which is almost a year ago now, so please
retrieve any new studies that have been done in that time and add to them.
3.Due to limited studies, only two results in the 10mg group were available for combining, other
doses were not applicable, please check that the methodology of the subgroup analyses is correct.
Title: The Role of Seladelpar in Primary Biliary Cholangitis: A Systematic Review and Meta-
Analysis
Version: 0 Date: 06 Feb 2025
Reviewer's report:
This article systematically evaluated the efficacy and safety of Seladelpar, a selective PPAR-
# agonist, for the treatment of primary biliary cholangitis (PBC). To address the conflicting
efficacy conclusions and insufficient long-term safety evidence in existing studies, the authors
integrated clinical trial data to clarify the clinical value of Seladelpar through a systematic review
and meta-analysis, and explored future research directions, aiming to provide an evidence-based
rationale for optimising therapeutic strategies for PBC.However, some drawbacks in the paper
necessitate revisions prior to publication.
1.There are some typos errors and grammatical issues through the manuscrip.
2.The authors retrieved studies up to March 2024, which is almost a year ago now, so please
retrieve any new studies that have been done in that time and add to them.
3.Due to limited studies, only two results in the 10mg group were available for combining, other
doses were not applicable, please check that the methodology of the subgroup analyses is correct.
Please review this paper.
user
Title: The Role of Seladelpar in Primary Biliary Cholangitis: A Systematic Review and Meta-
Analysis
Version: 0 Date: 06 Feb 2025
Reviewer's report:
This article systematically evaluated the efficacy and safety of Seladelpar, a selective PPAR-
# agonist, for the treatment of primary biliary cholangitis (PBC). To address the conflicting
efficacy conclusions and insufficient long-term safety evidence in existing studies, the authors
integrated clinical trial data to clarify the clinical value of Seladelpar through a systematic review
and meta-analysis, and explored future research directions, aiming to provide an evidence-based
rationale for optimising therapeutic strategies for PBC.However, some drawbacks in the paper
necessitate revisions prior to publication.
1.There are some typos errors and grammatical issues through the manuscrip.
2.The authors retrieved studies up to March 2024, which is almost a year ago now, so please
retrieve any new studies that have been done in that time and add to them.
3.Due to limited studies, only two results in the 10mg group were available for combining, other
doses were not applicable, please check that the methodology of the subgroup analyses is correct.
assistant